CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
March 29, 2016 18:12 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results"...
Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
March 29, 2016 16:30 ET
|
Argos Therapeutics, Inc.
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 – - Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3...
Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
March 23, 2016 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
March 22, 2016 16:05 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of fully...
Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
March 22, 2016 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics to Present at 2016 Keystone Symposia Conference “HIV Persistence: Pathogenesis and Eradication”
March 18, 2016 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 18, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics to Participate in Alliance for Regenerative Medicine Cell and Gene Therapy Investor Day
March 17, 2016 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 17, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Argos Therapeutics Announces Financing of Up to $60 Million
March 07, 2016 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
Dr. Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer
January 20, 2016 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
December 10, 2015 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...